# Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

> **NCT00911573** · PHASE3 · WITHDRAWN · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Skin Diseases
- Infection

## Interventions

- **DRUG:** Tigecycline
- **DRUG:** Clindamycin (or Vancomycin if needed)

## Key facts

- **NCT ID:** NCT00911573
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911573, "Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00911573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*